Novartis MS Drug Kesimpta Quick Out Of The Blocks
Strong Challenger To Roche's Ocrevus
Kesimpta is a treatment option for multiple sclerosis patients "that doesn't need compromise, the trade-off between high efficacy and high treatment burden," Novartis neuroscience chief Norman Putzki tells Scrip.
You may also be interested in...
Novartis Boosts Biologics Offering With $300m Investment In European Facilities
The funds will help advance biologic R&D, manufacturing and commercialization capabilities across Europe as the major pursues more sophisticated modalities, its global biologics head tells Scrip.
Novartis MS Franchise Boosted After Fending Off Last Gilenya Challenge
The Swiss firm expects no generic versions of Gilenya in the US market "for at least the next two years" after a court again ruled against HEC Pharma, the only remaining company challenging its patent.
Janssen’s Ponvory Will Face Stiff Competition In Europe’s MS Market
Janssen is the latest big pharma company to gain an approval for a new oral multiple sclerosis therapy in the EU, enhancing the competitiveness of the marketplace, and giving more choice for patients.